Government award will advance the company's non-vaccine influenza therapeutic, CD388, and onshore its manufacturing ahead of a potential pandemic.
Regulators expedite review for ALTO-101, targeting a key aspect of schizophrenia with no currently approved treatments.
The communications technology firm has completed its merger with Core Gaming and will relaunch on October 7th as an artificial intelligence holding company.
The sale of the controlling interest in the insurance platform represents a significant and rapid return on investment for White Mountains.
With a potential market of 128 million in the U.S., analysts see blockbuster potential for the new presbyopia treatment.
A notorious ransomware group claims to have stolen sensitive corporate data, putting Oracle's reputation and customer security under scrutiny.
Positive Phase 1 results for the company's epilepsy drug candidate are coupled with a significant financing deal that could dilute shares.
Tecentriq in combination with Zepzelca approved as a first-line maintenance treatment for extensive-stage small cell lung cancer, a significant advancement for a hard-to-treat cancer.